Compare OVBC & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | NYXH |
|---|---|---|
| Founded | 1872 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3M | 188.1M |
| IPO Year | N/A | 2021 |
| Metric | OVBC | NYXH |
|---|---|---|
| Price | $40.90 | $5.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 13.7K | ★ 35.2K |
| Earning Date | 01-27-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | ★ 3.01 | N/A |
| Revenue | ★ $64,211,000.00 | $6,616,215.00 |
| Revenue This Year | N/A | $75.27 |
| Revenue Next Year | N/A | $277.15 |
| P/E Ratio | $13.44 | ★ N/A |
| Revenue Growth | ★ 11.98 | 10.96 |
| 52 Week Low | $21.86 | $4.35 |
| 52 Week High | $42.00 | $11.87 |
| Indicator | OVBC | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 55.87 |
| Support Level | $38.59 | $4.45 |
| Resistance Level | $40.90 | $4.86 |
| Average True Range (ATR) | 0.93 | 0.23 |
| MACD | -0.17 | 0.05 |
| Stochastic Oscillator | 81.79 | 90.69 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services within Southeastern Ohio as well as western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers and other standard banking products and services.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.